BackRestart Life Sciences Overview

Restart Life Sciences Receivables

Track Restart Life Sciences's receivables ($30K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$30125.00

Peer trimmed avg / median

Loading

Restart Life Sciences Receivables History

Loading

Restart Life Sciences vs. peers: Receivables Comparison

Loading

Restart Life Sciences Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Restart Life Sciences (NMLSF) FAQ

The latest receivables for NMLSF is $30K as of February 2026. Investors often review this figure alongside Restart Life Sciences's historical trend and sector peers before judging valuation or financial health.

A receivables figure of $30K for NMLSF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NMLSF's receivables ($30K), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Restart Life Sciences's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.